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Abstract: (1) Background: We investigated the incidence and survival trends for pancreatic cancer (PC)
over the last 25 years in the Girona region, Catalonia, Spain; (2) Methods: Data were extracted from the
population-based Girona Cancer Registry. Incident PC cases during 1994–2015 were classified using
the International Classification of Diseases for Oncology Third Edition (ICD-O-3). Incidence rates
age-adjusted to the European standard population (ASRE) and world standard population (ASRW)
were obtained. Trends were assessed using the estimated annual percentage of change (EAPC)
of the ASRE13. Observed and relative survivals (RS) were estimated with the Kaplan–Meier and
Pohar Perme methods, respectively; (3) Results: We identified 1602 PC incident cases. According to
histology, 44.4% of cases were exocrine PC, 4.1% neuroendocrine, and 51.1% malignant-non-specified.
The crude incidence rate (CR) for PC was 11.43 cases-per-100,000 inhabitants/year. A significant
increase of incidence with age and over the study period was observed. PC overall 5-year RS was
7.05% (95% confidence interval (CI) 5.63; 8.84). Longer overall survival was observed in patients with
neuroendocrine tumours (5-year RS 61.45%; 95% CI 47.47; 79.55). Trends in 5-year RS for the whole
cohort rose from 3.27% (95% CI 1.69–6.35) in 1994–1998 to 13.1% (95% CI 9.98; 17.2) in 2010–2015;
(4) Conclusions: Incidence rates of PC in Girona have increased in the last two decades. There is a
moderate but encouraging increase in survival thorough the study period. These results can be used
as baseline for future research.
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1. Introduction
Pancreatic cancer (PC) is a major health problem in developed countries due to its high mortality
rate and its increasing incidence [1]. It used to be an uncommon neoplasm in the European Union
(EU) but now it ranks as the 7th most common form of cancer, representing 3.0% of all new cancer
cases [2]. Cancer incidence projections of GLOBOCAN (Global Cancer Observatory) 2018 point out
that the number of new cases will rise in the whole EU (+32%) by 2040, and up to +46% in Spain [3].
It is already the fourth leading cause of cancer death in Western countries, the 3rd in Spain [4], and in
the next 20 years its impact is expected to increase up to being the second leading cause of cancer death
and the main cause of lost years of quality-adjusted life (QALYs) [5].
More than 90% of malignant tumors of the pancreas arise from the exocrine pancreas,
with pancreatic ductal adenocarcinoma representing 85% of cases [6]. Its prognosis is ominous,
with overall survival rates under 20% one year after diagnosis and <10% at 5 years [7–10]. This has
been attributed, among other causes, to the premature vascular, lymphatic and perineural spread of
these tumors, which makes that most of the patients present disseminated disease at diagnosis [11].
Improvements in diagnostic tools and systemic treatments have been achieved in the last two decades
benefitting a small proportion of patients and, therefore, with only minimal impact on mortality. In this
context, PC represents a major challenge for cancer research and has fostered growing interest by
clinicians and epidemiologists.
PC etiology is still not well known. Established risk factors are smoking, high alcohol
consumption, diabetes mellitus, obesity, chronic pancreatitis, mucinous intra-ductal neoplasia (IPMN),
familial aggregation of PC and some hereditary syndromes (i.e., familial multifocal atypical melanoma,
Peutz–Jeghers syndrome and hereditary breast and ovarian cancer associated with BRCA mutations) [6].
Furthermore, up to 40 low-penetrance genetic variants have been associated with sporadic PC risk
based on GWAS (Genome-wide association study) in consortia of multiple PC studies. However,
these factors do not fully explain the variation in risk for PC, and familial risk and genetic syndromes
account for less than 10% of PC.
We conducted a population-based study of patients diagnosed with PC in Girona, a north-eastern
province of Spain with one of the oldest population cancer registries in the country with regular data
quality review, to analyze the incidence and survival trends for PC in the region.
2. Materials and Methods
2.1. Data Source
Data were extracted from the population-based Girona Cancer Registry (GCR)—in the northeast
of Spain (covering a population of 739,607 inhabitants in 2015)—during 1994–2015. Cases were
registered according to the International Agency for Research on Cancer (IARC) guidelines with a
completeness of 96.3%.
2.2. Study Population
The study included cases with PC (International Classification of Diseases for Oncology Third
Edition (ICD-O-3) histological codes: 8000, 8010, 8020, 8041, 8070, 8140, 8150, 8151, 8153, 8240, 8246,
8249, 8260, 8452, 8453, 8470, 8480, 8481, 8490, 8500, 8510, 8550, 8560 and 8971; topography C25) [12].
We excluded patients with tumors in situ and histologically verified stromal tumors, lymphomas and
sarcomas (n = 3 cases). Also, patients aged less than 15 years old at the date of PC diagnosis
were excluded. All cases were retrospectively revised individually. Tumors were categorized by
histological subtypes following the 4th edition of World Health Organisation (WHO) classification of
tumors of the digestive system [13], to ensure comparability. For the analysis, two main histological
subgroups were considered: pancreatic neuroendocrine tumours (PNET) and non-neuroendocrine PC
(non-PNET), besides, a third subgroup (non-HC PC) includes all cases without microscopic verification
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(Supplementary Table S1). The study population was further stratified by sex and grouped by age at
diagnosis into five categories: (15–44 y), (45–54 y), (55–64 y) and elderly persons (65–74 y and ≥75 y).
The primary site was defined following the ICD-O-3 codes C25.0–C25.9: Head of pancreas, (C25.0),
body of pancreas (C25.1), tail of pancreas (C25.2), pancreatic duct (C25.3), “others” including islets of
Langerhans (C25.4), other specified parts of pancreas (C25.7), overlapping lesion of pancreas (C25.8)
and pancreas, NOS (C25.9). Due to the low numbers of cases we jointly analysed the following codes:
C25.3 (ducts), C25.4 (islets+), C25.7 (other parts) and C25.8 (overlapping). In the Girona Cancer registry,
we collect retrospectively all NETs regardless of their behaviour (malign or uncertain) from 1994 until
now. All these cases were recoded following the 2010 international recommendation for codifying
NETs in cancer registries.
Survival analysis was performed on a dataset excluding cases identified by death certificate only
(DCO) and those cases diagnosed at autopsy (n = 119 cases). Follow up was defined from data of
diagnosis to date of last known vital status (death by any cause, date of loss of follow-up, or date of
end of follow-up at 31st December 2018). Vital status of patients was obtained by linking records to
the Catalan registry of Mortality and the National Death Index. We estimated 1- and 5-year observed
survival (OS) by sex, age-group, histological type (survival was analyzed jointly for both non-PNETs
and non-HC PC on the basis that they were more likely to be carcinomas), tumour location and period
of diagnosis. We did not calculate survival estimates when subgroups had <20 patients available
for analysis.
2.3. Study Outcomes and Statistical Analysis
For data analysis, version 3.4.3 of RStudio was used. Statistical significance was defined as
two-sided p < 0.05. The study focused in two main outcomes: incidence and survival. Incidence was
analyzed in terms of crude rate (CR) and estimates were age-standardized with the following
weights: world (ASRw), United States 2000 (ASRus2000), European 1976 (ASRE76) and European
2013 (ASRE13) standard populations. For the sake of simplicity, we will mainly refer to ASRE13 in the
text. Trends were assessed using the estimated annual percentage of change (APC) of the ASRE13.
The jointpoint loglinear regression version 4.5.0.1 model was used to calculate APC. To analyze
differences between sexes according to clinical and pathological characteristics, we used the T test
or Chi square test. Version 22.0.0 of SPSS and WebSurvCa [14] have been used for survival analysis.
Observed survival was calculated using the Kaplan–Meier method. To eliminate the possibility of
death from other causes, the relative survival was calculated using the Pohar–Perme estimator [15],
which represents the hypothetical survival that patients would have had if their cancer had been the
only possible cause of death. To calculate the net survival, we used life tables and general mortality
with the Edlant–Johnson method [16].
2.4. Ethics Approval
This study involves a secondary data analysis from existing data and records. The information
was recorded by the investigators in such a manner that subjects could not be identified, directly or
through identifiers linked to the subjects. The participating cancer registry has data management
policies in place allowing for the preservation of individual patients’ confidentiality including the
ethical approvals from local mandatory bodies. For this type of study, formal consent is not required.
3. Results
3.1. Baseline Characteristics
Table 1 shows the characteristics of the 1602 patients with PC identified in Girona during 1994–2015.
Of them, 46% were women and 54% men. The mean age at diagnosis was 70.57 years (range 19–101),
men were younger (68 years) than women (73 years), p < 0.001. DCO-cases were 7.5% in men and
7.3% in women. Patients over 64 years old represented 70% of cases (64.51% in males and 76.11%
Int. J. Environ. Res. Public Health 2020, 17, 9538 4 of 22
in females). Overall, 48.5% had a pathologically verified PC. Among them, non-PNETs accounted
for 91.63% of cases and PNETs 8.37% (4.06% of the whole series). Non-HC PC comprised the largest
group of PC in our study (51.5%, ASRE13 = 6.8 per 100,000 p-y). Within non-PNETs, the most frequent
histology was Adenocarcinoma (Supplementary Table S1). Staging information was only available in
613 patients, 415(67.69%) were stage IV.
Table 1. Distribution of pancreatic tumours characteristics according to sex. Girona 1994–2015.
Total Males Females p-Value
n (%) (% *) n (%) (% *) n (%) (% *)
AGE AT DIAGNOSIS ˆ <0.001
Mean 70.57 68.49 73.01
Median 72 70 75
Min-max 19–101 28–96 19–101
AGE GROUP (YEARS) + <0.001
15–44 52 (3.25) 29 (3.35) 23 (3.12)
45–54 150 (9.36) 98 (11.33) 52 (7.06)
55–64 281 (17.54) 180 (20.81) 101 (13.7)
65–74 432 (26.97) 262 (30.29) 170 (23.07)
75+ 687 (42.88) 296 (34.22) 391 (53.05)
BASIS OF DIAGNOSIS + <0.001
Death certificate only (DCO) 119 (7.43) 65 (7.51) 54 (7.33)
Clinical only 4 (0.25) 1 (0.12) 3 (0.41)
Clinical investigation 642 (40.07) 304 (35.14) 338 (45.86)
Cytology 251 (15.67) 148 (17.11) 103 (13.98)
Histology of a metastasis 155 (9.68) 91 (10.52) 64 (8.68)
Histology of a primary tumour 412 (25.72) 246 (28.44) 166 (22.52)
Unknown 19 (1.19) 10 (1.16) 9 (1.22)
TOPOGRAPHICAL SUB-SITE + 0.604
Head of the pancreas (C25.0) 658 (41.07) 357 (41.27) 301 (40.84)
Body of the pancreas (C25.1) 109 (6.8) 56 (6.47) 53 (7.19)
Tail of the pancreas (C25.2) 89 (5.55) 51 (5.89) 38 (5.15)
Other specified parts of the pancreas (C25.3,4,7,8) 61 (3.8) 28 (3.23) 33 (7.47)
Pancreas, NOS (C25.9) 685 (42.75) 373 (43.12) 312 (42.33)
HISTOLOGICAL GROUPS + <0.001
PNETs 65 (4.06) 37 (4.28) 28 (3.8)
Pancreatic carcinomas (non-neuroendocrine) 712 (44.44) 424 (49.02) 288 (39.08)
Pancreatic tumours non-histologically confirmed 825 (51.5) 404 (46.71) 421 (57.12)
TNM STAGE + 0.556
I 21 (1.31) (3.42) 10 (1.15) (3.04) 11 (1.49) (3.84)
IIA 37 (2.31) (6.03) 21 (2.43) (6.40) 16 (2.17) (5.61)
IIB 70 (4.37) (11.41) 41 (4.74) (12.5) 29 (3.93) (10.17)
III 70 (4.37) (11.41) 43 (4.97) (13.1) 27 (3.66) (9.47)
IV 415 (25.90) (67.69) 213 (24.62) (64.93) 202 (27.41) (70.87)
Unknown 989 (61.73) 537 (62.08) 452 (61.32)
PERIOD OF DIAGNOSIS + 0.993
1994–1998 239 (14.91) 128 (14.79) 111 (15.06)
1999–2003 327 (20.41) 177 (20.46) 150 (20.35)
2004–2009 453 (28.27) 246 (28.43) 207 (28.08)
2010–2015 583 (36.39) 314 (36.30) 269 (36.49)
TOTAL 1602 (100.0) 865(54.2) 737 (45.8)
PNETs—Pancreatic neuroendocrine tumours. TNM—Tumor node metastasis. (%) * Percentage with respect to the
n cases with confirmed stage (n = 613 for both sexes, n = 328 for males, and n = 286 for females).ˆ Results from t-test.
+ Results from Chi-Square test.
3.2. Incidence and Incidence Temporal Trends
The overall CR for the whole series was 11.43 cases per 100,000 inhabitants/year. Compared with
females, males had higher incidence rates: 12.17 versus 10.34, respectively. The overall ASRE13 was
13.19 (95% confidence interval (CI) 12.55; 13.85) and the ASRW was 5.68(95% CI 5.38; 6.01) (Table 2).
Age-specific rates reflected an increase with advancing age, having the Girona population over 85 years
the highest rate (74.5 cases per 100,000 inhabitants/year) (Figure 1). During the study period, the ASRE13
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gradually increased from 10.6 in 1994 to 14.21 in 2015, with a significant EAPC of 1.55%. This increase
was observed in both males (EAPC = 1.35%) and females (EAPC = 1.67%). No differences in incidence
rates between the geographical areas of Girona province have been found, and no significant cut-point
was identified by joinpoint regression. (Supplementary Table S2; Figure 2a–c).
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Figure 1. Age-specific incidence rates for pancreatic tumours of the overall population and according to sex.
Within the non-PNETs, the incidence trend evidences a gradual increase. Regarding the ASR,
results show an ASRE13 of 5.87 (95% CI 5.44; 6.32), that heightens with age (Table 2). During the study
period, the ASRE13 increased with a significant EAPC of 6%. No significant cut-point was identified by
joinpoint regression in this subgroup (Figure 2d).
In our study, PNETs represent only 4.06% of the whole series. The CR was 0.5 (95% CI 0.38; 0.63).
As for the ASR, results show an ASRE13 of 0.53 (95% CI 0.41; 0.68) and an ASRW of 0.33 (95% CI 0.25; 0.45).
Rates remain stable during 1994–2015 with a non-statistically significant EAPC of 3.16% (Figure 2e).
The subgroup of non-HC PC represents 51.5% of all cases. A proportion that was higher in females
than in males (57.12% vs. 46.71%). Incidence analyses reveal a total ASRE13 of 6.83 (95% CI 6.37; 7.32)
that hikes up to 45.9 (95% CI 41.9; 50.1) in >75-year-old patients (Table 2). Rates of non-histology
confirmed PC decreased through the whole study period (1994–2015) with a significant EAPC of
−2.23% (Figure 2f).
The increase in incidence rates applied for all age subgroups in our population, however the rate
of increase was more pronounced in older age groups, as reflected by an EAPC of 1.45% in patients
≥55 years old versus 0.59% in <55 year olds (Figure 2g,i). The difference in annual percent change by
age group was larger in Non-PNETs, with an EAPC of 0.6% for <55-year-old patients compared to
6.80% in ≥55 year olds (Figure 2h,j).
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Table 2. Incidence of pancreatic cancer (PC) in Girona, 1994–2015. European standard population of 2013 (ASRE13) according to histology. Non-PNET—Pancreatic
carcinomas non-neuroendocrine. PNET—Pancreatic neuroendocrine tumours. Non-HC—Pancreatic cancers non-histologically confirmed.
All PC Non-PNETs PNETs PC Non-HC
n % Total ASRE13 95% CI n % Total ASRE13 95% CI n % Total ASRE13 95% CI n % Total ASRE13 95% CI
Sex
Female 737 46 10.82 (10.05–11.65) 288 40.45 4.46 (3.95–5.01) 28 43.08 0.41 (0.27–0.6) 421 51.03 5.96 (5.4–6.57)
Male 865 54 15.8 (14.75–16.91) 424 59.55 7.35 (6.66–8.1) 37 56.92 0.6 (0.42–0.84) 404 48.97 7.85 (7.09–8.68)
Age Group (years)
15–44 52 3.25 0.85 (0.63–1.12) 27 3.79 0.44 (0.29–0.65) 19 29.23 0.3 (0.18–0.48) 6 0.73 0.1 (0.04–0.22)
45–54 150 9.36 8.16 (6.9–9.58) 106 14.89 5.75 (4.7–6.96) 13 20 0.7 (0.37–1.2) 31 3.76 1.71 (1.16–2.43)
55–64 281 17.54 19.32 (17.13–21.72) 191 26.83 13.14 (11.34 15.14) 10 15.38 0.69 (0.33–1.26) 80 9.7 5.5 (4.36–6.85)
65–74 432 26.97 35.66 (32.38–39.19) 221 31.04 18,23 (15.91–20.8) 11 16.92 0.9 (0.45–1.62) 200 24.24 16.52 (14.31–18.98)
75+ 687 42.88 61.83 (57.28–66.66) 167 23.46 14.87 (12.69 17.32) 12 18.46 1.06 (0.55–1.86) 508 61.58 45.91 (41.99–50.1)
STAGE
I 21 1.31 0.15 (0.07–0.32) 9 1.26 0.08 (0.02–0.21) 8 12.31 0.05 (0.01–0.17) 4 0.48 0.03 (0.01–0.14)
IIA 37 2.31 0.31 (0.22–0.43) 25 3.51 0.21 (0.14–0.32) 5 7.69 0.04 (0.01–0.09) 7 0.85 0.06 (0.02–0.12)
IIB 70 4.37 0.59 (0.46–0.75) 62 8.71 0.53 (0.4–0.68) 1 1.54 0.01 (0–0.04) 7 0.85 0.06 (0.02–0.12)
III 70 4.37 0.58 (0.45–0.74) 43 6.04 0.36 (0.26–0.49) 2 3.08 0.01 (0–0.05) 25 3.03 0.21 (0.13–0.31)
IV 415 25.90 3.40 (3.07–3.79) 251 35.25 2.06 (1.8–2.37) 21 32.31 0.16 (0.1–0.28) 143 17.33 1.18 (0.99–1.42)
TOTAL 1602 13.19 (12.55–13.85) 712 5.87 (5.44–6.32) 65 0.49 (0.38–0.63) 825 6.83 (6.37–7.32)
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male; (c) female; according to histological groups; (d) non PNETS; (e) PNETs; (f) non histological 
confirmation. According to age groups; (g) All PC ≥ 55 years-old; (h) Exocrine tumours ≥ 55 
years-old; (i) All PC < 55 years-old; (j) Exocrine tumours < 55 years-old. 
Figure 2. Trends in annual pancreatic tumors incidence (ASRE13) according to sex; (a) both sexes; (b)
male; (c) female; according to histological groups; (d) non PNETS; (e) PNETs; (f) non histological
confirmation. According to age groups; (g) All PC ≥ 55 years-old; (h) Exocrine tumours ≥ 55 years-old;
(i) All PC < 55 years-old; (j) Exocrine tumours < 55 years-old.
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3.3. Survival
The overall 5-year RS was 7.05% (95% CI: 5.63; 8.84), higher in men (7.34%) than in women (6.75%)
(Supplementary Figure S1). The survival rate decreased with advancing age at diagnosis, the 5-year RS
dropped from 34.23% in young patients (15–44 years) to 2.04% in older patients (75+ years) (Figures 3 and 4).
According to the stage at diagnosis, stage IIA showed a 5-year RS of 46.14% (95% CI 36.14; 58.91)
in contrast to the 4.36% (95% CI 2.61; 7.29) of stage IV. Trends in 5-year RS increased from 3.27%
(95% CI 1.69; 6.35) in 1994–98 to 13.1% (95% CI 9.98; 17.2) in 2010–15. No differences in survival rates
between the geographical areas of Girona province have been found (Table 3 and Figure 3a).
For non-PNETs and non-HC PC, overall 5-year RS was higher in men (4.75%) than in women
(2.9%). The survival rate was lower with increasing age, the 5-year RS decreased from 15.79% in young
patients (15–44 years) to 1.07% in older patients (75+ years). As for the stage at diagnosis, stage IIA
presented the best survival with a 5-year RS of 28.25% (95% CI 14.08; 56.67) and stage IV patients carried
the worst 5-year RS: 0.55% (95% CI 0.08; 3.89). Trends in 5-year RS rose from 1.06% (95% CI 0.36; 3.1) in
1994–98 to 7.76% (95% CI 5.22; 11.53) in 2010–15. No differences in survival between the geographical
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Figure 3. 5-year relative survival for all pancreatic cancers—PC (a), Pancreatic carcinomas non-neuroendocrine—Non PNETs (b) and Pancreatic neuroendocrine 
tumors—PNETs (c) by sex, stage, period of diagnosis, sub-site and county. Girona province, 1994–2015. 
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unspecified histology (malignant neoplasm) in our series. This weakness in registry-based studies of 
PC has been largely reported. In EUROCARE-4 [22], a study that collected data from 93 European 
cancer registries between 1995 and 2002, the microscopic verification rate was 63% (range 30–91%) 
for PC. What stands out from our data is the ASR behaviour of the non-HC PC, whose incidence rate 
gradually decreases with an EAPC of −2.23. These findings not only reflect the introduction and 
growing use of modern diagnostic techniques in our daily clinical practice, but also a change of 
attitude towards pancreatic cancer leaving nihilism behind. 
Figure 4. Age-specific period estimates of 5-year relative survival for all patients with pancreatic cancer
diagnosed between 1994–2015, and according to histology.
Finally, patients with PNETs had the best survival with a 5-year RS of 61.45% (95% CI 47.47; 79.55)
(Figure 4). Due the low number of cases we only analysed survival according to sex, age group and
period of diagnosis. No differences were observed by age or sex. The 5-year RS increased during the
study period from 45.2% (95% CI 23.28; 87.77) in 1994–1998 to 70.31 (95% CI 54.71; 90.36) in 2010–2015
(Table 5 and Figure 3c).
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Table 3. One and 5-year observed and relative survival for all pancreatic cancers by sex, age, stage, period of diagnosis, sub-site and county. Girona province, 1994–2015.
Observed Survival (OS) Relative Survival (RS)
n Cases 1–y OS 95% CI 1–y OS 5–y OS 95 %CI 5–y OS n Cases 1–y RS 95% CI 1–y RS 5–ys RS 95% CI 5–y RS
SEX
Female 681 20.46 (17.6–23.79) 4.18 (2.76–6.34) 681 26.46 (23.04–30.38) 6.75 (4.71–9.66)
Male 800 22.47 (19.69–25.65) 5.83 (4.28–7.95) 800 24.12 (21.28–27.34) 7.34 (5.53–9.76)
AGE GROUP (YEARS)
15–44 51 54.65 (42.51–70.25) 33.91 (22.57–50.95) 51 54.73 (42.72–70.11) 34.23 (22.99–50.95)
45–54 146 37.62 (30.37–46.61) 8.39 (4.6–15.31) 146 37.75 (30.52–46.68) 8.55 (4.77–15.32)
55–64 262 30.02 (24.8–36.36) 7.37 (4.51–12.05) 259 30.62 (25.33–37.02) 7.78 (4.81–12.59)
65–74 400 23.98 (20.05–28.67) 4.69 (2.82–7.8) 398 24.64 (20.62–29.43) 5.57 (3.42–9.07)
75+ 622 9.92 (7.8–12.63) 1.26 (0.57–2.77) 618 10.72 (8.43–13.64) 2.04 (0.96–4.35)
TOPOGRAPHICAL SUB–SITE
Head of the pancreas (C25.0) 644 26.26 (23–29.99) 4.26 (2.77–6.53) 644 30.7 (27.09–34.79) 6.05 (4.1–8.92)
Body of the pancreas (C25.1) 106 19.56 (13.13–29.15) 2.06 (0.52–8.11) 106 19.16 (13.28–27.64) 3.49 (1.19–10.29)
Tail of the pancreas (C25.2) 82 18.05 (11.28–28.88) 4.51 (1.55–13.1) 82 19.9 (13.61–29.09) 4.36 (1.83–10.39)
Other specified parts of the
pancreas (C25.3,4,7,8) 91 45.75 (36.53–57.3) 30.84 (22.23–42.79) 91 41.14 (32.93–51.4) 27.27 (19.5–38.15)
Pancreas, NOS (C25.9) 558 12.91 (10.36–16.1) 2.71 (1.56–4.7) 558 15.41 (12.48–19.02) 3.79 (2.37–6.05)
STAGE
I 21 – (NA–NA) – (NA–NA) 21 – (NA–NA) 0.26 (NA–NA)
IIA 37 62.49 (48.16–81.1) 36.87 (22.79–59.63) 37 66 (53.63–81.23) 46.14 (36.14–58.91)
IIB 69 60.58 (49.81–73.68) 15.4 (7.58–31.31) 69 56.12 (45.76–68.81) 12.67 (6.87–23.37)
III 70 33.34 (23.88–46.54) 4.62 (1.54–13.89) 70 37.55 (29.73–47.43) 5.56 (2.54–12.19)
IV 414 19.11 (15.57–23.45) 2.78 (1.37–5.63) 414 21.1 (17.43–25.53) 4.36 (2.61–7.29)
PERIOD OF DIAGNOSIS
1994–1998 217 16.69 (12.39–22.49) 2.78 (1.26–6.12) 217 18.09 (13.68–23.91) 3.27 (1.69–6.35)
1999–2003 289 14.18 (10.64–18.89) 2.48 (1.19–5.16) 289 16.39 (12.46–21.55) 3.38 (1.82–6.27)
2004–2009 415 23.04 (19.3–27.5) 4.66 (3–7.22) 415 27.44 (23.51–32.02) 6.68 (4.54–9.82)
2010–2015 560 26.45 (22.89–30.55) 9.65 (7.09–13.13) 560 31.45 (27.6–35.83) 13.1 (9.98–17.2)
GEOGRAPHICAL AREA
Alt Empordà Coast 224 21.99 (17.06–28.35) 5.98 (3.42–10.46) 224 26.25 (21.11–32.66) 8.79 (5.55–13.91)
Alt Empordà Interior 38 14.75 (6.25–34.85) 7.38 (2–27.16) 38 13.69 (7.09–26.42) 7.63 (2.83–20.54)
Baix Empordà 262 23.14 (18.49–28.95) 6.03 (3.5–10.4) 262 24.94 (20.23–30.74) 8 (5.24–12.2)
Cerdanya 24 12.5 (4.34–36.03) 4.17 (0.61–28.38) 24 13.87 (8.82–21.83) 7.25 (6.75–7.78)
Garrotxa 129 19.19 (13.42–27.45) 4.26 (1.82–9.96) 129 21.69 (15.77–29.83) 4.94 (2.41–10.1)
Gironès 343 21.09 (17.11–26) 4.02 (2.21–7.33) 343 25.98 (21.85–30.88) 5.85 (3.53–9.7)
Pla De L’Estany 62 26.28 (17.26–40.02) 3.5 (0.9–13.61) 62 34.21 (25.25–46.36) 3.73 (1.4–9.96)
Ripollès 87 17.43 (10.87–27.96) 3.08 (0.81–11.71) 86 18.29 (11.55–28.97) 3.69 (1.13–12.01)
Selva Coast 204 27.88 (22.19–35.01) 5.93 (3–11.73) 204 30.55 (24.71–37.78) 8.44 (5.2–13.7)
Selva Interior 108 14.18 (8.88–22.64) 5.88 (2.61–13.26) 108 17.38 (11.51–26.24) 8.74 (4.69–16.27)
TOTAL 1481 21.54 (19.5–23.79) 5.07 (3.95–6.51) 1481 24.94 (22.72–27.38) 7.05 (5.63–8.84)
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Table 4. One and 5-year observed and relative survival for non-PNETs and non-HC PC by sex, age, stage, period of diagnosis, sub-site and county. Girona province, 1994–2015.
Observed Survival (OS) Relative Survival (RS)
n Cases 1–y OS 95% CI 1–y OS 5–y OS 95 %CI 5–y OS n Cases 1–y RS 95% CI 1–y RS 5–ys RS 95% CI 5–y RS
SEX
Female 653 17.79 (15.04–21.04) 1.64 (0.82–3.29) 653 23.24 (19.75–27.33) 2.9 (1.61–5.21)
Male 763 20.21 (17.48–23.37) 3.62 (2.4–5.47) 763 21.78 (18.93–25.07) 4.75 (3.25–6.95)
AGE GROUP (YEARS)
15–44 32 37.5 (23.98–58.65) 15.62 (6.59–37.02) 32 37.56 (24.32–58.02) 15.79 (7.07–35.28)
45–54 133 34.35 (26.97–43.75) 4.94 (2.15–11.36) 133 34.47 (27.13–43.81) 5.04 (2.29–11.09)
55–64 252 27.88 (22.68–34.27) 4.6 (2.39–8.88) 249 28.45 (23.19–34.9) 4.88 (2.59–9.19)
65–74 389 22.65 (18.76–27.33) 2.89 (1.46–5.74) 387 23.27 (19.3–28.06) 3.54 (1.87–6.7)
75+ 610 8.99 (6.96–11.62) 0.57 (0.16–1.99) 606 9.73 (7.53–12.57) 1.07 (0.37–3.11)
TOPOGRAPHICAL SUB–SITE
Head of the pancreas (C25.0) 638 26.19 (22.92–29.93) 3.94 (2.51–6.16) 638 30.74 (27.11–34.86) 5.73 (3.83–8.58)
Body of the pancreas (C25.1) 105 19.75 (13.26–29.42) 2.08 (0.53–8.18) 105 19.16 (13.28–27.64) 3.5 (1.19–10.29)
Tail of the pancreas (C25.2) 78 13.67 (7.72–24.19) 0 (NA–NA) 78 15.9 (10.03–25.23) 0.05 (0.02–0.17)
Other specified parts of the
pancreas (C25.3,4,7,8) 57 18.01 (10.24–31.7) 2.33 (0.35–15.74) 57 20.73 (13.55–31.73) 2.62 (0.7–9.81)
Pancreas, NOS (C25.9) 538 11.44 (9–14.55) 1.83 (0.94–3.59) 538 13.89 (11–17.53) 2.65 (1.46–4.81)
STAGE
I 13 – (NA–NA) – (NA–NA) 13 – (NA–NA) – (NA–NA)
IIA 32 55.98 (40.45–77.47) 25.02 (12.29–50.91) 32 58.06 (42.18–79.92) 28.25 (14.08–56.67)
IIB 68 61.47 (50.65–74.61) 15.63 (7.69–31.75) 68 56.12 (45.77–68.81) 12.67 (6.87–23.37)
III 68 31.35 (22–44.68) 3.2 (0.82–12.44) 68 34.68 (27.1–44.37) 2.89 (0.93–8.93)
IV 393 17.27 (13.81–21.61) 1.86 (0.8–4.37) 393 19.61 (15.92–24.14) 3.48 (1.89–6.4)
PERIOD OF DIAGNOSIS
1994–1998 208 14.52 (10.43–20.21) 0.97 (0.24–3.84) 208 16.05 (11.73–21.97) 1.06 (0.36–3.1)
1999–2003 279 12.5 (9.13–17.11) 1.47 (0.56–3.89) 279 13.95 (10.3–18.9) 2.35 (1.08–5.12)
2004–2009 402 21.52 (17.83–25.97) 2.78 (1.56–4.99) 402 25.93 (21.87–30.75) 4.23 (2.51–7.14)
2010–2015 527 22.8 (19.33–26.89) 5.42 (3.44–8.55) 527 27.53 (23.63–32.08) 7.76 (5.22–11.53)
GEOGRAPHICAL AREA
Alt Empordà Coast 216 20.5 (15.65–26.87) 4.53 (2.34–8.79) 216 25.37 (19.95–32.26) 7.43 (4.24–13.03)
Alt Empordà Interior 38 14.75 (6.25–34.85) 7.38 (2–27.16) 38 13.69 (7.09–26.42) 7.63 (2.83–20.54)
Baix Empordà 242 18.38 (14.02–24.08) 1.25 (0.34–4.66) 242 19.24 (14.87–24.88) 2.1 (0.81–5.46)
Cerdanya 23 8.7 (2.31–32.69) 0 (NA–NA) 21 9.83 (3.09–31.3) 0.22 (0.02–2.58)
Garrotxa 124 16.68 (11.2–24.83) 1.81 (0.46–7.07) 124 19.13 (13.43–27.23) 1.88 (0.7–5.01)
Gironès 328 18.41 (14.58–23.25) 1.69 (0.62–4.61) 328 23.54 (19.45–28.48) 2.96 (1.38–6.35)
Pla De L’Estany 58 24.62 (15.63–38.79) 1.89 (0.27–13.14) 58 36.22 (26.85–48.84) 1.75 (0.44–6.92)
Ripollès 83 15.79 (9.43–26.42) 1.48 (0.21–10.22) 82 16.53 (10.03–27.24) 1.85 (0.4–8.55)
Selva Coast 199 26.49 (20.84–33.66) 4.53 (2.1–9.78) 199 28.54 (22.78–35.76) 5.83 (3.17–10.72)
Selva Interior 105 12.66 (7.62–21.01) 4.17 (1.55–11.24) 105 15.54 (9.99–24.17) 6.83 (3.3–14.13)
TOTAL 1416 19.08 (17.09–21.3) 2.71 (1.9–3.87) 1416 22.31 (20.05–24.83) 4.01 (2.88–5.59)
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Table 5. One and 5-year observed and relative survival for PNETs by sex, age, stage, period of diagnosis, sub-site and county. Girona province, 1994–2015.
Observed Survival (OS) Relative Survival (RS)
n Cases 1–y OS 95% CI 1–y OS 5–y OS 95 %CI 5–y OS n Cases 1–y RS 95% CI 1–y RS 5–ys RS 95% CI 5–y RS
SEX
Female 28 81.82 (68.57–97.62) 68.33 (52.12–89.56) 28 63.63 (55.42–73.06) 61.17 (51.85–72.17)
Male 37 67.27 (53.65–84.34) 51.38 (36.97–71.42) 37 65.32 (51.12–83.45) 53.65 (37.32–77.12)
AGE GROUP (YEARS)
15–44 19 83.88 (68.71–100) 66.09 (47.14–92.65) 19 84 (69.21–101.94) 66.57 (48.06–92.21)
45–54 13 69.23 (48.19–99.47) 47.47 (24.93–90.4) 13 69.39 (49.09–98.07) 48.2 (26.65–87.19)
55–64 10 80 (58.68–100) 68.57 (44.47–100) 10 80.36 (59.95–107.72) 71.39 (47.32–107.72)
65–74 11 71.59 (48.84–100) 61.36 (37.69–99.92) 11 72.56 (50.57–104.1) 68.83 (43.57–108.74)
75+ 12 58.33 (36.16–94.1) 43.75 (20.86–91.77) 12 61.42 (39.06–96.58) 51.86 (25.51–105.44)
TOPOGRAPHICAL SUB–SITE
Head of the pancreas (C25.0) 6 33.33 (10.75–100) 33.33 (10.75–100) 6 33.51 (12.7–88.41) 34.11 (12.93–90)
Body of the pancreas (C25.1) 1 0 (NA–NA) 0 (NA–NA) 1 0.03 (0–0.22) 0.03 (0–0.22)
Tail of the pancreas (C25.2) 4 100 (100–100) 75 (42.59–100) 4 100 (100–100) 82.47 (50.94–133.54)
Other specified parts of the
pancreas (C25.3,4,7,8) 34 91.18 (82.12–100) 76.55 (62.56–93.67) 34 87.77 (75.23–102.4) 81.77 (64.89–103.02)
Pancreas, NOS (C25.9) 20 52.87 (34.4–81.24) 32.9 (16.24–66.65) 20 60.11 (46.4–77.86) 39.95 (23.52–67.84)
STAGE
I 8 – (NA–NA) – (NA–NA) 8 – (NA–NA) – (NA–NA)
IIA 5 100 (100–100) 100 (100–100) 5 100 (100–100) 106.46 (106.46–106.46)
IIB 1 0 (NA–NA) 0 (NA–NA) 1 0.03 (0–0.22) 0.03 (0–0.22)
III 2 100 (100–100) 50 (12.5–100) 2 100 (100–100) 57.71 (18.81–177.01)
IV 21 51.95 (34.31–78.66) 28.05 (11.96–65.81) 21 51.45 (36.42–72.7) 34.83 (20.62–58.85)
PERIOD OF DIAGNOSIS
1994–1998 9 66.67 (42–100) 44.44 (21.41–92.27) 9 67.18 (43.7–103.27) 45.2 (23.28–87.77)
1999–2003 10 60 (36.17–99.52) 30 (11.64–77.32) 10 60.38 (37.63–96.87) 32.95 (14.24–76.28)
2004–2009 13 69.23 (48.19–99.47) 61.54 (40.04–94.58) 13 69.8 (56.02–86.96) 68.08 (54.17–85.57)
2010–2015 33 81.38 (68.98–96.02) 72.66 (57.68–91.51) 33 81.2 (68.9–95.7) 70.31 (54.71–90.36)
GEOGRAPHICAL AREA
Alt Empordà Coast 8 62.5 (36.54–100) 46.88 (21.49–100) 8 63.07 (38.45–103.46) 48.1 (24.06–96.17)
Alt Empordà Interior 20 79.69 (63.73–99.63) 67.61 (49.04–93.22) 20 73.82 (56.89–95.8) 59.81 (42.09–84.98)
Baix Empordà 1 100 (100–100) 100 (100–100) 1 100 (100–100) 100 (100–100)
Cerdanya 5 80 (51.61–100) 60 (29.33–100) 5 80.32 (54.1–119.23) 62.04 (33.12–116.23)
Garrotxa 15 80 (62.12–100) 54 (32.22–90.51) 15 78.89 (64.45–96.56) 63.59 (48.16–83.97)
Gironès 4 50 (18.77–100) 25 (4.58–100) 4 50.02 (22.1–113.22) 25.07 (7–89.75)
Pla De L’estany 4 50 (18.77–100) 50 (18.77–100) 4 52.94 (23.63–118.62) 58.18 (25.97–130.34)
Ripollès 5 80 (51.61–100) 80 (51.61–100) 5 80.84 (54.53–119.86) 82.27 (55.49–121.98)
Selva Coast 3 66.67 (29.95–100) 66.67 (29.95–100) 3 66.88 (34.83–128.44) 68.59 (35.72–131.71)
Selva Interior 8 62.5 (36.54–100) 46.88 (21.49–100) 8 63.07 (38.45–103.46) 48.1 (24.06–96.17)
TOTAL 65 73.6 (63.57–85.21) 58.69 (47.28–72.84) 65 70.28 (58.67–84.19) 61.45 (47.47–79.55)
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4. Discussion
We present the first registry-based data on trends in PC incidence and survival rates in Spain for
all histological types, including neuroendocrine tumors.
Our results for the Girona province revealed an upward trend in PC incidence throughout the
study period regardless of sex, age, tumour location, stage, period of diagnosis and geographical area.
In contrast with Wood et al. [7] who reported a stable or even decreasing trend, our findings concur with
recent publications that report a stepwise increase of PC incidence in the last decades, especially evident
in developed countries [4,6,17–20]. According to the prevailing worldwide tendency [4], in the
current study PC incidence is higher in men than in females and increases with age for both sexes,
with 70% of patients being older than 64 years at diagnosis. The aging and longevity of the population,
the increasing incidence of obesity and adult-onset diabetes, and exposure to risk factors such as
smoking, and some dietary habits (consumption of red and processed meat or excessive alcohol intake,
for example) may partially account for the present findings [21].
In our series we found 51.5% of PC without microscopic verification, a higher result than the
proportion published in other studies [17]. Obtaining tissue for diagnosis can be notoriously difficult
in patients with suspected PC and it often requires invasive methods, such as ultrasound-guided
biopsies or even surgery. These procedures can be challenging in elderly patients or in those with
poor performance status, reason whereby we believe there is a high proportion of PC with unspecified
histology (malignant neoplasm) in our series. This weakness in registry-based studies of PC has been
largely reported. In EUROCARE-4 [22], a study that collected data from 93 European cancer registries
between 1995 and 2002, the microscopic verification rate was 63% (range 30–91%) for PC. What stands
out from our data is the ASR behaviour of the non-HC PC, whose incidence rate gradually decreases
with an EAPC of −2.23. These findings not only reflect the introduction and growing use of modern
diagnostic techniques in our daily clinical practice, but also a change of attitude towards pancreatic
cancer leaving nihilism behind.
There is growing evidence supporting an association between adult weight gain, childhood or
adolescent obesity, and increased risk of colorectal, endometrial, and pancreatic cancers [23]. Sung et al.
have recently reported an increasing of PC incidence in young adults compared to >45-year-old
population, and linked it to excess bodyweight, obesity-related health conditions and lifestyle
factors [24]. Unlike them, although in our study PC incidence is growing in all age groups, we found a
greater rise of incidence trend in older people (≥55 years old) compared with younger adults (<55 years
old), and the difference was more evident when we limited our analysis to non-PNET histologically
confirmed cases. This could be explained by two main reasons: first, the low number of cases diagnosed
<45 years old (n = 52); and, second, although in Spain obesity rates in adolescents and young adults
are rising due to changes in life-style and diet [25], it is a recent issue and it is not reflected yet in the
PC incidence rates during the study period.
In accordance with previously reported data [5,11,26], most cases (n = 613) were diagnosed in
stage IV (67.69%). This data reflects the absence of specific symptoms in the early stages of pancreatic
tumors. Even in the highest income countries most PC patients are diagnosed with metastatic or locally
advanced disease [27], a fact which determines the poor survival of PC patients worldwide.
Survival for PC, as reported in the EUROCARE-5 study [10], is particularly low: European average
RS is 26% at one year and 7% at five years since diagnosis, similar to what we found in our series
(Figure 3). In accordance with previously published data [8], survival decreased with advancing age in
our study, except for PNETs, where we found no differences among age groups.
We observed better survival in males than in females, and this is a previously unreported finding.
In Europe, 5-year RS was similar in both sexes when considering European regions or countries [10].
Looking back to the demographic characteristics of our population (Table 1), two important data
stand out: the median age of the female cohort is higher than the males’ (75 y vs. 70 y) and the main
difference lies in the proportion of population over 75 y at time of PC diagnosis (34% of males and
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53% of females). As age is one of the strongest prognostic factors for PC, this may explain the poor
outcomes of females in our study.
As expected, due to the different etiology and biology of the PNET neoplasms [28,29], survival was
much higher than for the rest of the study population (the non-PNETs). The 5-year RS for this
subgroup was 61.45 (95% CI 47.47; 79.55), above those observed in Europe for the period 2000–2007:
42.9% (95% CI 41.0; 44.8) [30]. Following the whole series tendency, it improved thorough the study
timeframe. When we approach PNETs’ survival results, it is to note that since 2010, the international
recommendation for the registration of PNET in cancer registries has changed. The new stage
classification of NETs is based on histological grades, thus since its implementation all NETs should be
registered, whereas until then only invasive cases were registered. In Girona all cases were recoded
following these recommendations, and due to this fact, PNETs survival may have improved. Unlike in
the rest of PC, females presented better survival than males, and survival was similar among the age
groups studied.
With regards to survival rates in non-PNETs, irrespective of being microscopically confirmed or
not, encouraging progress in survival over time was detected. We did not only find an increase in
1-year RS, but also, in contrast with the published data from the UK [31] and the Canadian Cancer
Registry [32], an upswing in the 5-year RS from 1.06% (95% CI 0.36; 3.1) in the initial lustrum (1994–1998)
to 7.76% (95% CI 5.22; 11.53) in the last time period of the study (2010–2015). We have an ongoing
higher resolution study in order to analyze the treatment regimens received by this population and
their impact on survival.
Strengths and Weaknesses
Strengths of this study include the use of real-world data from a high-quality population-based
Cancer Registry, the large sample size, and the long-term and virtually complete follow-up of the
population that yield robust survival. However, the study presents some limitations that should be
kept in mind when interpreting our results: first the territory-linked data as a result of being the
Regional Cancer Registry as our source of information. Second, we had missing information on clinical
variables such as AJCC (American Joint Committee on Cancer) stage and tumour location for more
than half of the study population. And third, we lacked information on tumour histology in 51%
of patients.
4.1. Conclusions
We present a large, comprehensive, and up-to-date analysis of incidence and survival data of
all PC in Girona (Spain) obtained from a high-quality cancer registration system. To the authors’
knowledge, this is the first population-based study in Spain to analyse both incidence and survival
trends for PC. Our results revealed an upward trend in PC incidence throughout the study period
regardless of sex, age, tumour location, stage, period of diagnosis and geographical area, as well as
an encouraging increase in survival in recent years. PNETs diagnosis had the best survival rates.
Among non-PNETs or non-HC PC, advanced age and stage were associated with poorer survival rates.
This information will contribute to estimate the burden of PC in Spain and will serve as a baseline for
future analysis, allowing comparison with other registries’ data.
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PNETS Pancreatic neuroendocrine tumours
Non PNETs Pancreatic carcinomas non-neuroendocrine
Non-HC PC Pancreatic cancers non-histologically confirmed
ASR Age-standardized rate
EAPC Estimated annual percentage change
CR Crude rate
RS Relative survival
GWAS Genome-wide association study
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